Literature DB >> 3652025

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.

W T Creasman1, C P Morrow, B N Bundy, H D Homesley, J E Graham, P B Heller.   

Abstract

The surgical pathologic features of 621 patients with Stage I carcinoma of the endometrium are presented. All patients were treated with primary surgery consisting of total abdominal hysterectomy, bilateral salpingo-oophorectomy, selective pelvic and paraaortic lymphadenectomy and peritoneal cytology. An appreciable number of patients (144-22%) with Stage I cancers have disease outside of the uterus (lymph node metastasis, adnexal disease, intraperitoneal spread and/or malignant cells in peritoneal washings). Multiple prognostic factors particularly grade and depth of invasion are related to extrauterine disease. This study adds credence to the primary surgical approach with individualized postoperative therapy as indicated.

Entities:  

Mesh:

Year:  1987        PMID: 3652025     DOI: 10.1002/1097-0142(19901015)60:8+<2035::aid-cncr2820601515>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  274 in total

Review 1.  Management of gynaecological cancers.

Authors:  A Melville; A Eastwood; J Kleijnen; H Kitchener; P Martin-Hirsch; L Nelson
Journal:  Qual Health Care       Date:  1999-12

2.  Management of stage 1 endometrial carcinoma. Postoperative radiotherapy is not justified in women with medium risk disease.

Authors:  M P Burger
Journal:  BMJ       Date:  2001-03-10

3.  Current status in the management of uterine corpus cancer in Korea.

Authors:  Nan-Hee Jeong; Jong-Min Lee; Seon-Kyung Lee
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

4.  Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.

Authors:  P Mhawech-Fauceglia; R F Herrmann; J Kesterson; I Izevbaye; S Lele; K Odunsi
Journal:  Eur J Surg Oncol       Date:  2010-12       Impact factor: 4.424

5.  Asian society of gynecologic oncology workshop 2010.

Authors:  Dong Hoon Suh; Jae Weon Kim; Mohamad Farid Aziz; Uma K Devi; Hextan Y S Ngan; Joo-Hyun Nam; Seung Cheol Kim; Tomoyasu Kato; Hee Sug Ryu; Shingo Fujii; Yoon Soon Lee; Jong Hyeok Kim; Tae-Joong Kim; Young Tae Kim; Kung-Liahng Wang; Taek Sang Lee; Kimio Ushijima; Sang-Goo Shin; Yin Nin Chia; Sarikapan Wilailak; Sang Yoon Park; Hidetaka Katabuchi; Toshiharu Kamura; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

6.  Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysis.

Authors:  Thomas Papathemelis; Dunja Hassas; Michael Gerken; Monika Klinkhammer-Schalke; Anton Scharl; Michael P Lux; Mathias W Beckmann; Sophia Scharl
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-23       Impact factor: 4.553

Review 7.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

Review 8.  Endometrial cancer: the management of high-risk disease.

Authors:  Gunnar Kristensen; Claes Tropé
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

9.  How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study.

Authors:  Sokbom Kang; Jong-Min Lee; Jae-Kwan Lee; Jae Weon Kim; Chi-Heum Cho; Seok-Mo Kim; Sang-Yoon Park; Chan-Yong Park; Ki-Tae Kim
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

10.  The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.

Authors:  Nick M Spirtos; Danielle Enserro; Howard D Homesley; Susan K Gibbons; David Cella; Robert T Morris; Koen DeGeest; Roger B Lee; David S Miller
Journal:  Gynecol Oncol       Date:  2019-04-30       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.